Nathanael Gray, PhD

Nancy Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology in the Field of Medical Oncology, Dana-Farber Cancer Institute
Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia.
Authors: Authors: Liu X, Hunter ZR, Xu L, Chen J, Chen JG, Tsakmaklis N, Patterson CJ, Castillo JJ, Buhrlage S, Gray N, Treon SP, Yang G.
Br J Haematol
View full abstract on Pubmed
CDK7-dependent transcriptional addiction in triple-negative breast cancer.
Authors: Authors: Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ.
Cell
View full abstract on Pubmed
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Authors: Authors: Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H.
Cancer Discov
View full abstract on Pubmed
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
Authors: Authors: Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA.
Mol Oncol
View full abstract on Pubmed
Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.
Authors: Authors: Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J.
J Clin Invest
View full abstract on Pubmed
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Authors: Authors: Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP.
Blood
View full abstract on Pubmed
Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations.
Authors: Authors: de Wispelaere M, Du G, Donovan KA, Zhang T, Eleuteri NA, Yuan JC, Kalabathula J, Nowak RP, Fischer ES, Gray NS, Yang PL.
Nat Commun
View full abstract on Pubmed
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Authors: Authors: Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Düster R, Geyer M, Sim T, Marto JA, Sorger PK, Westover KD, Lin CY, Kwiatkowski N, Gray NS.
Cell Chem Biol
View full abstract on Pubmed
Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
Authors: Authors: Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, Becht K, Kim ND, McKeown MR, Roberts JM, Zhang J, Sim T, Alessi DR, Bradner JE, Lizcano JM, Blacklow SC, Qi J, Xu X, Gray NS.
ACS Chem Biol
View full abstract on Pubmed
Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8.
Authors: Authors: Hatcher JM, Wang ES, Johannessen L, Kwiatkowski N, Sim T, Gray NS.
ACS Med Chem Lett
View full abstract on Pubmed